Novocure shares plunged after the provider of cancer-fighting treatments reported a Phase 3 trial of its Tumor Treating Fields (TTFields) therapy for ovarian cancer patients failed to meet its goal.
Novocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet Goal
by admin 0 Comments